Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 5,230 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Clear all
Completed No phase listed Observational

Gilead Sustained Virologic Response (SVR) Registry

NCT01457755
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
6,625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
162
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 29, 2026, 5:12 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

NCT06672978
View directory record Official record
Conditions
Acute Pyelonephritis, Complicated Urinary Tract Infection
Interventions
Meropenem-Vaborbactam, Antibiotics
Drug
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Industry
Eligibility
3 Months to 11 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Little Rock, Arkansas • Orange, California • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus

NCT01645735
View directory record Official record
Conditions
Infections
Interventions
Ceftaroline fosamil, Ceftriaxone plus vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Sylmar, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 29, 2026, 5:12 AM EDT
Terminated Phase 3 Interventional Results available

Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase

NCT04160468
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions
Exebacase, Placebo
Drug
Lead sponsor
ContraFect
Industry
Eligibility
12 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
55
States / cities
Birmingham, Alabama • Orange, California • Sacramento, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Results available

Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)

NCT01604850
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SOF, RBV, Placebo to match SOF, Placebo to match RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
51
States / cities
Coronado, California • Los Angeles, California • San Diego, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Not applicable Interventional Results available

Implementation of a Molecular Diagnostic for Pediatric Acute Gastroenteritis: The FilmArray GI Panel IMPACT Study

NCT02248285
View directory record Official record
Conditions
Infectious Gastroenteritis
Interventions
FilmArray™ Gastrointestinal (GI) Panel
Device
Lead sponsor
BioFire Diagnostics, LLC
Industry
Eligibility
Up to 18 Years
Enrollment
1,545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Los Angeles, California • Kansas City, Missouri • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 29, 2026, 5:12 AM EDT
Recruiting Phase 1 Interventional

Intraneural Administration of scAAV9/JeT-GAN Into the Vagus Nerve for Patients With Giant Axonal Neuropathy (GAN)

NCT07543991
View directory record Official record
Conditions
Giant Axonal Neuropathy (GAN)
Interventions
scAAV9/JeT-GAN
Genetic
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
10 Years to 25 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose Comparison Study of Menactra® in US Children

NCT00700635
View directory record Official record
Conditions
Meningitis, Meningococcal Infection, Neisseria Meningitidis
Interventions
Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
2 Years to 10 Years
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
15
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Boca Raton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Phase 2Phase 3 Interventional

Study of Combivir for Patients With Primary Biliary Cirrhosis

NCT00490620
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Combination antiviral therapy, Placebo
Drug
Lead sponsor
University of Alberta
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 1, 2007 · Synced Oct 29, 2026, 5:12 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

Botswana Tenofovir Oral HIV Prophylaxis Trial

NCT00111150
View directory record Official record
Conditions
HIV Infection
Interventions
Tenofovir Disoproxil Fumarate 300 mg daily
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 29 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2007 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Phase 2 Interventional

Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup)

NCT00001359
View directory record Official record
Conditions
Mental Disorder Diagnosed in Childhood, Obsessive Compulsive Disorder, Streptococcal Infection, Tic Disorder
Interventions
Penicillin or Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 5:12 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Role of Tissue Oxygenation and the miR-210 Gene In Wound Healing

NCT02024243
View directory record Official record
Conditions
Non-Diabetic Patients, Wound Leg, Chronic Ulcer Leg/Foot
Interventions
Not listed
Lead sponsor
Chandan Sen
Other
Eligibility
30 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
3
States / cities
Indianapolis, Indiana • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 29, 2026, 5:12 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

NCT04199689
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
9vHPV Vaccine, Placebo (Saline for Injection)
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
6,033 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
32
States / cities
Northridge, California • Rialto, California • Simi Valley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 29, 2026, 5:12 AM EDT
Not listed Not applicable Interventional

A Comparative Study to Assess the Prevention of Surgical Site Infection (SSI's) in Revision Total Joint Arthroplasty Patients Treated With Single-Use Negative Pressure Wound Therapy (PICO™) or Standard Care Dressings (AQUACEL® Ag SURGICAL Dressing)

NCT02664168
View directory record Official record
Conditions
Surgical Wound Infection
Interventions
Aquacel Ag Surgical Dressing, Single-Use Negative Pressure Wound Therapy (PICO)
Device
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Not applicable Interventional Results available

VasQ External Support for Arteriovenous Fistula

NCT03242343
View directory record Official record
Conditions
Arterio-Venous Fistula, ESRD, Steal Syndrome, Aneurysm, Renal Failure, Renal Disease, Diabetes Mellitus, Kidney Failure
Interventions
VasQ
Device
Lead sponsor
Laminate Medical Technologies
Industry
Eligibility
18 Years to 80 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Peoria, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 29, 2026, 5:12 AM EDT
Recruiting Phase 3 Interventional

The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal

NCT07142408
View directory record Official record
Conditions
Surgical Wound Infection
Interventions
Chlorhexidine gluconate (4%), Mupirocin 2% Ointment
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
848 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media

NCT02567825
View directory record Official record
Conditions
Acute Otitis Media
Interventions
Tympanostomy tube placement, Amoxicillin-Clavulanate and/or Ceftriaxone, Ofloxacin Otic
Device · Drug
Lead sponsor
Alejandro Hoberman
Other
Eligibility
6 Months to 35 Months
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Oct 29, 2026, 5:12 AM EDT
Completed No phase listed Observational

Prevalence of Hepatitis C Virus Infection in HIV-Infected Children

NCT00037076
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 20 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Results available

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis

NCT02201901
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
49
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

NCT02543567
View directory record Official record
Conditions
Healthy
Interventions
Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp), MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.], MVA-BN-Filo 5*10^7 Inf. U., Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
525 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 29, 2026, 5:12 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Rapid HIV Tests for Women Late in Pregnancy and During Labor

NCT00046436
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
7,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 29, 2026, 5:12 AM EDT
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

NCT05070364
View directory record Official record
Conditions
Hepatitis Delta Virus
Interventions
Peginterferon Lambda-1a
Drug
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Los Angeles, California • Redwood City, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 29, 2026, 5:12 AM EDT
Completed No phase listed Observational

Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma

NCT00981097
View directory record Official record
Conditions
Lymphoma, Nonneoplastic Condition
Interventions
polymerase chain reaction, laboratory biomarker analysis
Genetic · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 29, 2026, 5:12 AM EDT
Completed Phase 2 Interventional Results available

Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

NCT02136797
View directory record Official record
Conditions
CMV Infection, Persistent CMV Viremia
Interventions
CMVpp65 Specific T-cells
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 29, 2026, 5:12 AM EDT